1. Effectiveness and safety of apixaban vs warfarin among older venous thromboembolism patients stratified by race. (14th October 2021) Authors: Cohen, A; Sah, J; Dhamane, A; Lee, T; Rosenblatt, L; Hlavacek, P; Emir, B; Keshishian, A; Yuce, H; Luo, X Journal: European heart journal Issue: Volume 42(2021)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Effectiveness and safety of apixaban vs warfarin among older venous thromboembolism patients: a subgroup analysis of age. (14th October 2021) Authors: Cohen, A; Sah, J; Dhamane, A; Lee, T; Rosenblatt, L; Hlavacek, P; Emir, B; Keshishian, A; Yuce, H; Luo, X Journal: European heart journal Issue: Volume 42(2021)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Effectiveness and safety of apixaban vs warfarin among venous thromboembolism patients using five US databases: a subgroup analysis of chronic liver disease. (14th October 2021) Authors: Cohen, A; Sah, J; Dhamane, A; Lee, T; Rosenblatt, L; Hlavacek, P; Emir, B; Keshishian, A; Yuce, H; Luo, X Journal: European heart journal Issue: Volume 42(2021)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Effectiveness and safety of apixaban, low-molecular weight heparin, and warfarin among high-risk subgroups of venous thromboembolism patients with active cancer. (25th November 2020) Authors: Cohen, A; Keshishian, A; Lee, T; Wygant, G; Rosenblatt, L; Hlavacek, P; Sah, J; Luo, X Journal: European heart journal Issue: Volume 41:(2020)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗